Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Slightly older piglets (7–10 days old, 3.0–4.5 kg, males and females) were subjected to HI (n = 21) and sham (n = 6) procedures for neuropathology outcomes and scalp EEG recordings with survival of 4 days.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Proceedings of the National Academy of Sciences of the United States of America · 2025
Study scale: It works as follows: The input image is distributed into N (flattened 2D) patches (where we keep N = 6 for the MNIST experiments), and linear embeddings of these patches are fed as input to the encoder of the trained ViT.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
Not reported in the declared source.
Study scale
It works as follows: The input image is distributed into N (flattened 2D) patches (where we keep N = 6 for the MNIST experiments), and linear embeddings of these patches are fed as input to the encoder of the trained ViT.
Intervention or exposure
Not reported in the declared source.
Comparator
Not reported in the declared source.
Outcomes examined
By parametrically varying synaptic conductances within physiologically realistic bounds, we quantified the distinct computational roles of each inhibitory subtype in shaping pyramidal output and circuit-level dynamics (Fig. 2 D and E).
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
In this study, we explored the hypothesis that delivery of ABE using novel self-assembling receptor targeted lipid nanoparticles (RTN) and conversion of G542X to G542R could lead to a therapeutically functional treatment.
Study design
Not reported in the declared source.
Participants or experimental system
We used an adenine base editor (ABE8e Cas9) and guide RNA (sgRNA)/enhanced green fluorescent protein (EGFP) plasmids encapsulated in receptor targeted nanoparticles (RTN), delivered to Bmi-1 transduced basal human CF airway epithelial cells harbouring the homozygous CFTR G542X variant, to convert the stop codon to G542R, a variant which is amenable to modulator therapy.
Study scale
(n = 3) using OdysseyCLx fluorescence data.
Intervention or exposure
Treatment with ETI was performed 24 h prior to functional assessment with 1 μM VX-445, 3 μM VX-661, and 1 μM VX-770.
Comparator
Treatment with IL-1β was used as a positive control.
Outcomes examined
We assessed editing efficiency of ABE delivered as plasmid DNA also encoding EGFP, by RTN to CFTR G542X homozygous airway epithelial cells.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Given the indispensable role of SCN VIP neurons in maintaining circadian rhythm (5), we examined here the effect of mitofusin 2 (Mfn2), a mitochondrial membrane protein involved in the control of the fusion process (19), on SCN VIP neuronal activity and downstream effects on behavior, thermoregulation, and sleep.
Study design
To visualize VIP neurons, Cre-dependent tdTomato reporter control Ai14 mice (Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J; strain JAX:007914) crossed with Mfn2–/– mice were used for histological analysis and ex vivo electrophysiological recordings at the age of 1.5–3 months.
Participants or experimental system
To determine the effect of the SCN circadian oscillation in the LD cycle at the cellular level, we first analyzed synapse density and mitochondrial morphology in SCN core VIP- expressing neurons of C57BL/6J mice at Zeitgeber times (ZT) 1, 7, 13, 19, (ZT0: lights on; ZT12: lights off).
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Compared with the control animals, they had shifted activity onset toward the light phase, resulting in higher activity counts during the light phase and statistically lower activity counts during the dark phase, but without changes in their total activity level (Figure 4, D and E).
Outcomes examined
Along with mitochondria modifications in SCN VIP neurons of Mfn2–/– mice, we analyzed daily rearrangements of the number of synapses in these neurons.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Here, we tested whether GluN2C/D‐containing NMDARs mediate NMDAR currents in the IC, as well as the role of these receptors in synaptic integration and sound processing.
Study design
The signal was developed using the horseradish peroxidase for each channel and then opal dyes diluted at 1:1000 were assigned for each channel: tdTomato was assigned to Opal 690 (catalog. no. FP1497001KT; Akoya Bioscience, Marlborough, MA, USA), Glun2c was assigned to Opal 570 (catalog. no. FP1488001KT; Akoya Bioscience), and Glun2d was assigned to Opal 520 (catalog. no. FP1487001KT; Akoya Bioscience).
Participants or experimental system
Animals were kept under a 12:12 h light/dark photocycle with food and water available ad libitum.
Study scale
Male (n = 18) and female (n = 15) mice aged P30–P66 were used.
Intervention or exposure
Recording pipettes were pulled from borosilicate glass capillaries (outer diameter 1.5 mm, inner diameter 0.86 mm; Sutter Instrument) with a P‐1000 microelectrode puller (Sutter Instrument) and filled with an internal solution containing (in mm): 115 CsOH, 115 d‐gluconic acid, 7.76 CsCl, 0.5 EGTA, 10 HEPES, 10 Na2 phosphocreatine, 4 MgATP and 0.3 NaGTP, supplemented with 0.1% biocytin (w/v), pH adjusted to 7.4 with CsOH and osmolality to 290 mosmol kg–1 with sucrose.
Comparator
To test for vehicle effects, we performed control experiments where puff‐elicited EPSCs were compared between control and DMSO (vehicle) conditions.
Outcomes examined
Co‐localization of Glun2c and Glun2d in tdTomato‐positive neurons was quantified manually using Neurolucida 360 (MBF Bioscience, Williston, VT, USA).
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: This boosting of sensory responses did not occur when the prior trial was a Miss to the same whisker, or > 1 Hit to a different whisker (Fig. 4D, E, n = 6 mice, 70 sessions, 6906 PYR cells, 4–19 sessions per mouse, 118.7 ± 5.96 cells (range: 3–213) per session).
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Here, we developed an experimental model of focal attention based on reward history in the mouse whisker tactile system and used it to investigate the neurobiological basis of attention in the sensory cortex.
Study design
Not reported in the declared source.
Participants or experimental system
We studied attentional behavior in head-fixed mice during a Go/NoGo whisker touch detection task, which included Go stimuli on many different whiskers.
Study scale
This boosting of sensory responses did not occur when the prior trial was a Miss to the same whisker, or > 1 Hit to a different whisker (Fig. 4D, E, n = 6 mice, 70 sessions, 6906 PYR cells, 4–19 sessions per mouse, 118.7 ± 5.96 cells (range: 3–213) per session).
Intervention or exposure
To motivate behavioral training, each mouse received 0.8–1.5 mL of water daily, calibrated to maintain 85% of pre-training body weight.
Comparator
When the prior trial was a NoGo, mice detected the current Go whisker with d’ = 1.13 ± 0.02 (termed d’NoGo, mean ± SEM across 476 sessions, 22 mice), which we consider baseline detection sensitivity. d’ for detecting a given Go whisker was elevated following 1 prior Hit to the same whisker, and even more so following multiple consecutive Hits to the same whisker (d’>1HitSame = 2.45 ± 0.11, p = 1.0e-4 vs d’NoGo, permutation test).
Outcomes examined
Expert mice effectively distinguished Go from NoGo trials, quantified by d’ from signal detection theory (Supplementary Fig. S1A).
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Spatial learning performance was evaluated using the active place avoidance (APA) test from day 25 to day 30 (Figure 1A).
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
After admission, the enrolled patients were divided into two groups by SPSS computer randomization method: one group was TGP group, and the other group was conventional treatment group.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Sixty-five AP patients were randomly divided into conventional treatment group and TGP group.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: Naïve n = 6, Naïve RTX: n = 5; Day 1: Veh: n = 4, RTX: n = 4; Day 8: Veh: n = 5, RTX: n = 5; Day 10: Veh: n = 13, RTX: n = 5; Day 11: Veh: n = 13, RTX: n = 5; Day 15: Veh: n = 5, RTX: n = 5.
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Next, we determined whether nociceptors regulated pro-inflammatory-cytokine production before lung infection clearance.
Study design
All in vivo cells were gated on leukocytes, singlets, live, CD45+.
Participants or experimental system
To confirm the B cell-neutrophil axis, naïve neutrophils were incubated with decomplemented serum harvested from sensory neuron intact and RTX ablated mice, which underwent our pre-exposure and infection model, as well as naïve mice.
Study scale
Naïve n = 6, Naïve RTX: n = 5; Day 1: Veh: n = 4, RTX: n = 4; Day 8: Veh: n = 5, RTX: n = 5; Day 10: Veh: n = 13, RTX: n = 5; Day 11: Veh: n = 13, RTX: n = 5; Day 15: Veh: n = 5, RTX: n = 5.
Intervention or exposure
Data from 2 independent experiments. f–i B cells were isolated from spleens of naïve mice and cultured in media with IL4 + LPS and supplemented with VIP or NPY.
Comparator
Mice received escalating doses of resiniferatoxin (RTX) or Vehicle (Veh) starting 21 days prior to inoculation.
Outcomes examined
Given the high expression of VIPR1 on B cells, we tested the effects of VIP stimulation in WT and VIPR1–/– isolated B cells.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Given the described hepatoprotective role of IL-22, we hypothesize that modulation of this neuroimmune circuit could potentially be an innovative approach for the control of liver steatosis.
Study design
Not reported in the declared source.
Participants or experimental system
We used a model of diet-induced MASLD by exposing mice to a high-fat diet (HFD) for 16 weeks, when the development of liver steatosis was first observed in our animals.
Study scale
Average based on n = 6 in each group.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not reported in the declared source.
Outcomes examined
We characterized IL-22 production by intestinal ILC3 at this dietary endpoint.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not reported in the declared source.
Outcomes examined
To evaluate the antimicrobial activity of VIP (Sigma Aldrich, cat number V6130-250UG) the experiments were performed in a 96-well plate (Corning, Coastar, Cat number 3591).
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked